Devices › Device types
FDA product code OUT · class 3 · Unknown
Intracranial aneurysm flow diverter: medical device reports filed with FDA
12,075 reports carry this product code, 2011–2026; 12 brands with a page.
- 12,075
- reports with this product code
- 0.1% of all MAUDE reports
- 1,774
- reports, 12 months to August 2026
- 1,589 in the 12 months before
- 62%
- classified as malfunction
- 62.3% across all reports
- 5.2%
- classified as death, as reported
- 0.9% across all reports
Product code OUT is FDA's classification for "Intracranial aneurysm flow diverter" (unknown panel), a class 3 device. 12,075 medical device reports carry this product code, 0.1% of the MAUDE database, from August 2011 to August 2026.
1,774 reports arrived in the 12 months to August 2026, up 12% from 1,589 in the 12 months before. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases. The event types recorded are malfunction (62%), injury (32.8%) and death (5.2%). 12 brand names with a page on this site carry this code; the brands table is ordered by report count for navigation only. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Brands with this product code
| Brand | Reports | Latest 12 months | Classified as death | Classified as malfunction |
|---|---|---|---|---|
| Pipeline Flex W/Shield Technology | 3,293 | 922 | 2.2% | 84.5% |
| Pipeline Flex | 2,600 | 391 | 1.4% | 88.5% |
| Pipeline Embolization Device | 2,035 | 0 | 10.3% | 25.6% |
| Pipeline Flex Embolization Device | 838 | 31 | 7.8% | 66.8% |
| Pipeline Vantage With Shield Technology | 801 | 96 | 3% | 74.5% |
| Pipeline | 732 | 61 | 21.8% | 19.9% |
| Fred 27 | 223 | 13 | 5.3% | 10.6% |
| Unknown_Neurovascular_Product | 72 | 48 | 12.9% | 15.3% |
| Web Sl | 3 | 130 | 3.1% | 55.2% |
| Solitaire Fr | 2 | 93 | 12.3% | 56.2% |
| Marathon | 1 | 66 | 5.9% | 54.9% |
| Onyx Avm | 1 | 27 | 4.9% | 21.7% |
Ordered by report count for navigation only. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Manufacturers named
| Manufacturer (as written on reports) | Reports | Share |
|---|---|---|
| Micro Therapeutics Ev3 | 7,053 | 58.4% |
| Covidien Irvine | 1,396 | 11.6% |
| Ev3 Neurovascular | 1,258 | 10.4% |
| Stryker Neurovascular Cork | 966 | 8% |
| Microvention | 598 | 5% |
| Ev3 | 2 | 0% |
| Stryker Neurovascular-Utah-Salt Lake City | 2 | 0% |
Reports by month, five years
FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases.
Event type and report source
Event type
Who filed
Grey bar: all 26,136,888 MAUDE reports.
Device problems coded
| Device problem (FDA code) | Reports | Share |
|---|---|---|
| Activation failure | 5,781 | 47.9% |
| Physical resistance/sticking | 1,732 | 14.3% |
| Material deformation | 1,370 | 11.3% |
| Retraction problem | 650 | 5.4% |
| Activation, positioning or separation problem | 597 | 4.9% |
| Breakthe device broke | 501 | 4.1% |
| Unintended movement | 474 | 3.9% |
| Positioning failure | 403 | 3.3% |
| Difficult to open or close | 278 | 2.3% |
| Migrationthe device moved from where it was placed | 276 | 2.3% |
| Unintended ejection | 243 | 2% |
| Material twisted/bent | 239 | 2% |
| Device operates differently than expectedthe device behaved unexpectedly | 224 | 1.9% |
| Material frayed | 217 | 1.8% |
| Insufficient device problem information | 209 | 1.7% |
| Structural problem | 191 | 1.6% |
| Difficult to removethe device was hard to remove | 158 | 1.3% |
| Premature activation | 150 | 1.2% |
| Deformation due to compressive stress | 148 | 1.2% |
| Migration or expulsion of device | 147 | 1.2% |
Questions about intracranial aneurysm flow diverter reports
What is product code OUT?
FDA's classification code for "Intracranial aneurysm flow diverter", class 3, reviewed by the unknown panel. Every device report carries the product code of the device involved.
How many reports carry this code?
12,075 reports through August 2026, 1,774 of them in the latest 12 months.
Which brands appear most often?
Pipeline Flex W/Shield Technology (3,293), Pipeline Flex (2,600), Pipeline Embolization Device (2,035), Pipeline Flex Embolization Device (838) and Pipeline Vantage With Shield Technology (801). Widely used products collect more reports because more people use them.
Can the brands table be used to rank the devices?
No. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." Brands differ in how many are in use, how long they have been sold and how reports are collected.
Where this comes from. Counts are built from the openFDA Device Adverse Event (MAUDE) bulk export released 28 Sep 2026, which holds reports FDA received through 31 Aug 2026. Brand, generic and manufacturer names are as written on the reports; product code names come from FDA's device classification. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.